1G. Cruccu, C. Sommer, P. Anand,et al. EFNS guidelines on neuropathic pain assessment: revised 2009. [J]. European Journal of Neurology,2010,17 : 1010 - 1018.
2N. Attal, G. Cruccu, R. Baron, et al. EFNS guidelines on the pharmacological treatment of neuropathicpain: 2010 revision [ J ]. European Journal of Neurology,2010,17 : 1113 - 1123.
3Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol. 2001,429( 1 -3) :23 -37.
4Machelska H, Mousa SA, Brack A,et al. Opioid control of inflammatory pain regulated by intercellular adhesion molecule - 1. J Neurosci. 2002, 22(13): 5588 -5596.
5Rutkowski MD, Lambert F, Raghavendra V, et al. Presence of spinal B7.2 ( CD86 ) but not B7. 1 (CD80) co - stimulatory molecules following peripheral nerve injury: role of nondestructive immunity in neuropathic pain.J Neuroimmunol. 2004 Jan, 146(1-2):94-98.
6Tanga FY, Raghavendra V, DeLeo JA. Quantitative real-time RT- PCR assessment of spinal microglial and astrocytic activation markers in a rat model of neuropathic pain. Neurochemistry International. 2004, 45 (2 -3): 397 -407.
7Raghavendra V, Tanga FY, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003, 306( 2 ): 624 -630.
8Alexander Brack, Heike L. Rittner, Halina Machelska, et al. Control of inflammatory pain by chemokine - mediated recruitment of opioid - containing polymorphonuclear cells. Pain. 2004, 112(3): 229 -238.
9Brack A , Rittner HL , Machelska H , et al. Endogenous peripheral antinociception in early inflammation is not limited by the number of opioid-containing leukocytes but by opioid receptor expression. Pain. 2004,108(1 -2): 67 -75.
10Rittner HL, Brack A, Machelska H, et al. Opioid peptide-expressingleukocytes: identification, recruitment, and simultaneously increasing inhibition of inflammatory pain. Anesthesiology. 2001,95(2) :500 -508.
